[A18-07] Ribociclib (breast cancer) – Addendum to Commission A17-45
Last updated 19.03.2018
Project no.:
A18-07
Commission:
Commission awarded on 22.01.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Result of dossier assessment:
Unchanged conclusion compared with dossier assessment A17-45
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-45 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |